pravastatin

Ligand id: 2953

Name: pravastatin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: pravastatin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 11
Topological polar surface area 124.29
Molecular weight 424.25
XLogP 2.28
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease. The EMA approved a fixed-mixture drug (Pravafenix®) in 2011 which contains pravastatin and fenofibrate.
Mechanism Of Action and Pharmacodynamic Effects
Competitive inhibitor of HMG-CoA reductase, the enzyme catalysing the rate-limiting step of cholesterol synthesis. Acting primarily in the liver, pravastatin decreases hepatic cholesterol concentrations. The DrugBank record for this compound (accessed via the cross-link on the Summary tab) provides a comprehensive description of its molecular mechanism of action.
External links